$中国抗体-B(03681)$ SinoMab BioScience (HKG:3681) dosed the first patient in a phase 2 clinical trial of SM17 in China, according to a Wednesday Hong Kong bourse filing.
$中国抗体-B(03681)$ SinoMab BioScience (HKG:3681) dosed the first patient in a phase 2 clinical trial of SM17 in China, according to a Wednesday Hong Kong bourse filing.
精彩评论